Signal Genetics

Home

Webinar

Classify the Disease Define the Risk

Better informed decisions for the management of multiple myeloma

Learn about MyPRS®

Is the only clinically validated, comprehensive commercially available gene expression profile for multiple myeloma

Is validated in more than 4500 patients in 4 countries and in 17 unique patient data sets; reported in numerous peer-reviewed publications

Provides a detailed analysis already interpreted for you; over 1000 genes produce clear and actionable results

As Published In:

  • Leukemia
  • BMC Medical Geonomics
  • blood
  • Mayo Clinic
  • haematologica
  • cancer.net
  • British Journal of Haematology

What is ?

Myeloma Prognostic Risk Signature

Not just a gene expression profile but a panel of tests delivering more information about an individual patient's Multiple Myeloma than any other test alone or in combination.


Example Image

Signal Genetics

Get the advantage

Take the subjectivity out of multiple myeloma management.

Signal Genetics, Inc., is a commercial stage, molecular diagnostic company focused on providing innovative diagnostic services that help physicians make better informed decisions concerning the care of their patients suffering from cancer.

 

CLIA certified

Reference lab

Offering the only commercially available test of its kind, MyPRS

From its state-of-the-art, CLIA-certified reference laboratory located in Little Rock, Arkansas, Signal Genetics offers the unique flagship product, Myeloma Prognostic Risk Signature, or MyPRS. This test analyzes a whole-genome expression profile (GEP) of the patient's tumor cells and uses proprietary, well-validated algorithms to generate a personalized prognosis assessment and molecular characterization of the disease.

Back to top